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Abstract
Background: The durability of isoniazid preventive therapy (IPT) in preventing tuberculosis (TB) is limited in high-
prevalence settings. The underlying mechanism (reactivation of persistent latent TB or reinfection) is not known. We
aimed to investigate the timing of TB incidence during and after IPT and associated risk factors in a very high TB
and HIV-prevalence setting, and to compare the observed rate with a modelled estimate of TB incidence rate after
IPT due to reinfection.
Methods: In a post-hoc analysis of a cluster-randomized trial of community-wide IPT among South African gold
miners, all intervention arm participants that were dispensed IPT for at least one of the intended 9 months were
included. An incident TB case was defined as any participant with a positive sputum smear or culture, or with a
clinical TB diagnosis assigned by a senior study clinician. Crude TB incidence rates were calculated during and after
IPT, overall and by follow-up time. HIV status was not available. Multivariable Cox regression was used to analyse
risk factors by follow-up time after IPT. Estimates from a published mathematical model of trial data were used to
calculate the average reinfection TB incidence in the first year after IPT.
Results: Among 18,520 participants (96 % male, mean age 41 years, median follow-up 2.1 years), 708 developed TB.
The TB incidence rate during the intended IPT period was 1.3/100 person-years (pyrs; 95 % confidence interval (CI),
1.0–1.6) and afterwards 2.3/100 pyrs (95 % CI, 1.9–2.7). TB incidence increased within 6 months followed by a stable
rate over time. There was no evidence for changing risk factors for TB disease over time after miners stopped IPT.
The average TB incidence rate attributable to reinfection in the first year was estimated at 1.3/100 pyrs, compared
to an observed rate of 2.2/100 pyrs (95 % CI, 1.8–2.7).
Conclusions: The durability of protection by IPT was lost within 6–12 months in this setting with a high HIV
prevalence and a high annual risk of M. tuberculosis infection. The observed rate was higher than the modelled rate,
suggesting that reactivation of persistent latent infection played a role in the rapid return to baseline TB incidence.
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Background
The world has seen an upsurge in tuberculosis (TB) inci-
dence since the advent of the human immunodeficiency
virus (HIV) epidemic in the 1990s. This rise was mainly
seen in the sub-Saharan African region, which accounts
for 74 % of the annual 1.2 million people living with
HIV who develop TB [1]. In southern Africa, HIV preva-
lence among people with TB disease is around 50 %.
Isoniazid preventive therapy (IPT) is part of the World
Health Organization (WHO)’s 3Is strategy formulated to
reduce the burden of TB in people living with HIV [2].
A 6–12 month course of daily isoniazid has been shown
to reduce TB incidence in those with a positive tubercu-
lin skin test (TST) by an average of 60 % [3]. In a recent
randomised controlled trial of IPT in patients on anti-
retroviral therapy (ART), those with a negative TST at
enrolment also benefitted [4], although these partici-
pants could have undergone TST conversion whilst on
ART [5]. A large cluster-randomised trial of community-
wide IPT among 78,744 gold mine workers in South
Africa, the Thibela TB study [6], did not find a protective
effect of IPT on TB incidence or TB prevalence at a
population level. At an individual level, the direct pro-
tective effect of IPT was calculated in the subset of the
study population included in the baseline prevalence
survey, which was a random sample of the total work-
force. This showed a 58 % (95 % confidence interval
(CI), 12–80 %) lower incidence rate of TB during the
9 months on IPT versus that in a control cohort. How-
ever, this protective effect disappeared within the first
9 months after the intended IPT period.
Other studies have also shown that the effect of IPT
wanes over time in settings with high annual risks of
Mycobacterium tuberculosis infection [4, 7–9]. Few IPT
trials have reported data on long-term TB incidence
rates after IPT discontinuation, and on how these rates
change over time. Additional file 1: Table S1 gives an
overview of long-term follow-up data of the adult trials.
The Bethel studies in the pre-HIV era showed a durable
effect over a long period of time, but were performed in
a context of reducing TB transmission and other TB
control strategies [10, 11]. In contrast, the studies per-
formed in TB high-prevalence settings showed a rapid
increase in TB incidence rates after IPT cessation. The
underlying mechanism (reactivation of persistent latent
infection or reinfection) is not well understood.
The relatively small numbers of events in these co-
horts have limited the power to investigate the timing of
TB occurring after IPT cessation and the change of asso-
ciated risk factors over time. We therefore set out to
analyse TB incidence in the entire Thibela TB study
population that had received IPT. This population was
almost four times as large as the IPT cohort used to cal-
culate the direct effect of the intervention, which were
the participants included in the baseline survey only (a
random sample of 1,000 miners per cluster on whom
more in-depth data was collected) [6].
Our study objectives were four-fold: to estimate the
TB incidence rate during and after IPT (objective 1); to
investigate risk factors associated with incident TB after
IPT (objective 2); and to determine whether these dif-
fered over time after the end of IPT (effect modification
by follow-up period, objective 3). All three analyses used
both the intended and actual duration of IPT (Fig. 1).
Our final objective was to compare the observed inci-
dence of TB in the first year after IPT with a crude
estimate of the average incidence rate of TB disease due
to reinfection that might have occurred during that
period (objective 4).
Methods
Study design and setting: Thibela TB trial
This was a post-hoc analysis of data from the Thibela TB
study, a cluster-randomised trial to investigate the
impact of community-wide IPT on TB incidence and
prevalence compared to standard of care among 15 clus-
ters (mine shafts) of gold mine workers in South Africa
[6]. Clusters were randomised to the intervention (TB
screening offered to the entire cluster linked to treat-
ment for TB disease or infection, as appropriate; eight
clusters) or control (standard of care, seven clusters)
As treated
Intention to treat
Time 0 (objective 2+3)
IPT (intended period of 9 months) Follow-up
Time 0 (objective 2+3)
IPT (actual period) Follow-up
Time 0 (objective 1)
Time 0 (objective 1)
Fig. 1 Start of the risk period (time 0) in the intention-to-treat and as-treated analyses. Follow-up was maximum 12 months after the end of
intended isoniazid preventive therapy for the last participant in each cluster.
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arm [12]. The study methods are described in full
elsewhere [12].
This analysis focused solely on the eight intervention
clusters. Within each cluster, the same procedure was
followed for enrolment and follow-up (Additional file 1:
Figure S1). All mine workers within the cluster were in-
vited to participate [13]. As 89 % of the workforce was
estimated to be infected with M. tuberculosis, TST was
deemed unnecessary [14]. Consenting miners were
screened for TB using a symptom screen and a chest X-
ray; a sputum smear and culture was ordered for miners
with signs or symptoms suggestive of TB. Positive
laboratory results and/or high clinical suspicion were
reason for referral to the mine health services for
further investigation and, if necessary, TB treatment.
Participants without evidence of active TB or contra-
indications to IPT were offered 9 months of IPT
(300 mg isoniazid daily) [15]. During IPT, participants
were seen monthly by study staff for dispensing of
study medication, and a symptom screen for TB and
adverse events. Symptomatic patients were referred to
the mine health services for further work-up and
management. After cessation of IPT, participants were
evaluated for incident TB during 6-monthly or annual
routine chest X-ray screening by occupational health
services or after self-presentation with symptoms to
the mine health services.
Population included in post-hoc analysis
All participants in the eight intervention clusters who
were prescribed IPT at least once and who were perman-
ent employees were included in this analysis. For analyses
involving follow-up after the end of IPT, only participants
who had completed the IPT period without a TB diagno-
sis, alive and still in the workforce, were included. In each
cluster, follow-up was continued until 1 year after the end
of the last participant’s intended IPT period.
Definitions and measurement of variables
Baseline characteristics of study participants were col-
lected by a questionnaire at enrolment into the interven-
tion and prior to initiation of IPT. At the request of the
trade unions, no HIV testing was performed for study
purposes. However, use of ART as concomitant medica-
tion was asked with respect to assessing possible adverse
events. HIV prevalence among miners was estimated at
29 % in 2000 [16]. IPT dispensing dates were recorded;
the number of monthly refill visits was used as a proxy
of adherence (≥6 defined as optimal, 6 months being a
recommended duration for IPT at the time the trial was
designed [17]). The end of the intended IPT period was
defined as 270 days from the first prescription date and
the end of the actual IPT period as 30 days from the last
dispensing date.
For estimation of the TB incidence rate, the start of
the risk period was defined as the date of IPT initiation
(objective 1); for the risk factor analyses the risk period
started at the end of the intended or actual IPT period
(objectives 2 and 3).
Miners with symptoms or signs suggesting TB were
investigated and treated by the mine health services.
Data on these episodes were obtained from record re-
view. Routine diagnostic workup included sputum smear
microscopy and a chest X-ray. Only one mining com-
pany routinely used mycobacterial culture to evaluate all
miners with signs/symptoms suggestive of TB, the others
only for those with a history of prior TB treatment.
However, during the study, we endeavoured, following
additional consent, to collect an additional sputum sam-
ple for smear microscopy and culture, though full cover-
age of this was not achieved. Cultures showing only
non-tuberculous mycobacteria were not considered as
TB. TB diagnoses were categorised as definite (2 positive
smears or 1 positive culture for M. tuberculosis, or
histological evidence of TB at autopsy in TB cases only
ascertained post-mortem), probable (1 positive smear or
culture with unidentified mycobacteria) or possible
(clinical or radiological signs and symptoms, but no or
negative smear/culture results). Medical records of par-
ticipants with possible TB were reviewed by senior study
clinicians, masked to study arm, to arbitrate on whether
to include as incident TB.
Employment records were used to determine dates of
employment and reasons for leaving the workforce (in-
cluding deaths). Miners who died and underwent aut-
opsy which revealed histological evidence of TB were
included as incident TB cases.
The end of the risk period was defined as the earliest
of TB treatment initiation (irrespective of the method of
diagnosis), termination from the workforce, death or the
end of follow-up. Participants who left the workforce
due to being ‘medically boarded’ (discontinuing employ-
ment for a medical reason) were all evaluated by the
mine healthcare system for active TB prior to the end of
employment, and we therefore assumed that none of
these represented missed TB diagnoses.
Statistical methods
The primary analyses were carried out using the
intended IPT period to define the end of IPT (intention-
to-treat (ITT), Fig. 1). Three sensitivity analyses were
conducted: an as-treated (AT) analysis using the actual
end date of IPT (Fig. 1), an AT analysis restricted to
those with optimal adherence (defined as having been
dispensed ≥6 months of IPT, see below), and a repeat
analysis of both the ITT and AT analyses with a stricter
TB case definition restricted to definite and probable TB
diagnoses.
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We calculated the overall TB incidence rate after initi-
ation of IPT and period-specific rates during and after
IPT. Poisson regression analyses adjusted for clustering
by mine shaft were used to calculate TB incidence rates
and to determine the rate ratio for TB after stopping
IPT compared to during IPT. We investigated trends in
TB incidence rates over time after the end of IPT using
tests for linearity and departure from linearity.
Multivariable Cox regression analysis was used to in-
vestigate risk factors for TB following the end of IPT.
We included factors we considered a priori as risk fac-
tors for TB (sex, age, previous TB, number of years in
the workforce, type of work (reduced ventilation with
underground work), housing (crowding in hostels), self-
reported use of ART and number of times IPT was dis-
pensed). The potential confounder (country of origin)
was retained in the model if inclusion led to a change in
hazard ratio estimate. In case of co-linearity, the more
important of the co-linear variables was determined by
literature review and retained. We considered previous
TB might be on the causal pathway as it has been shown
to be a risk factor for recurrent TB [18, 19]. We there-
fore examined the effect of dropping this variable in the
final multivariable Cox model. The effect of excluding
self-reported ART use was also examined. The final
model was adjusted for calendar time.
Clustering was controlled for with a fixed effect for
cluster in all regression analyses. Random effects analysis
was not used due to small number of clusters [20]. Clus-
ter estimates were not reported.
Departure from the proportional hazards assump-
tion was tested in objective 3: we incorporated inter-
action terms between the time period of follow-up
and the a priori risk factors. To maximise power, we
used unadjusted analyses and two time periods: <12
and ≥12 months after stopping IPT. This time split
was chosen to correspond with the expected timing
of different underlying mechanisms (reactivation of
inadequately treated latent infection <12 months ver-
sus reinfection ≥12 months), extrapolated from a
study of recurrent disease after treatment [21].
For the AT analysis, these procedures were repeated
using the actual end date of IPT as defined above. Two-
sided P values in regression analyses were derived from
likelihood ratio tests. Departure from linearity was tested
for all ordered categorical variables. The analyses were
conducted using STATA version SE 12.1 (College
Station, Texas, USA).
Comparison between observed and modelled TB
incidence in the first year after IPT
We applied base-case assumptions used in the published
mathematical model of the Thibela study data to calcu-
late a crude estimate of the average incidence rate of TB
disease attributable to reinfection in the first year after
IPT [22]. We did this overall and by cluster to allow for
the varying annual risk of infection per cluster. We
thereby assumed an annual risk of infection (averaged
across clusters) before the intervention of 20 % per year
and, based on outputs from the original model [22], a
reduction in the annual risk of infection ranging be-
tween 11–20 % after IPT was introduced. For all clusters
we assumed an HIV prevalence of 30 % of whom 25 %
had a CD4 count below 200 cells/μL (and all of whom
were eligible for and on ART), an initial pre-treatment
loss to follow-up of 40 % and an average time to detec-
tion of 1 year. The age distribution and prevalence of
silicosis depended on the cluster and were based on data
collected as part of the study. The origin of these as-
sumptions are explained in detail elsewhere [22]. Fur-
thermore, also based on the original model, we assumed
that reinfection, but no progression, could take place
during IPT. We then calculated the observed TB inci-
dence rate in the first 12 months after IPT (ITT), overall
and per cluster, and compared these rates to the mod-
elled estimates of TB incidence.
Ethical review
The Research Ethics Committees of University of
KwaZulu-Natal, South Africa, and the London School of
Hygiene & Tropical Medicine (LSHTM) as well as the
South African Medicines Control Council and the South
African Safety in Mines Research Advisory Committee
gave approval for the Thibela TB study. The LSHTM
ethics committee gave approval for this post-hoc sec-
ondary data analysis. Miners who participated in the
intervention provided written or witnessed oral informed
consent.
Results
Between July 2006 and February 2010, 18,520 partici-
pants were prescribed IPT at least once and were per-
manent employees. Their baseline characteristics are
described in Table 1; 96 % were men, in keeping with
the demographics of this workforce, with a median age
of 41 years and a median time in the mining workforce
of 18 years. Overall, 57 % of mine workers were South
African, 91 % worked mainly underground, 59 % lived in
a hostel, and 12 % reported having had TB previously
and 2.7 % as being on ART. IPT was dispensed six or
more times to 11,293 (61 %) participants, three to five
times to 2,125 (12 %), and once or twice to 5,102 (28 %)
participants.
TB incidence rate during and after IPT
Across all clusters, 708 participants developed TB during
37,321 person-years (pyrs). Of these, 55 % were definite,
12 % probable and 33 % possible diagnoses; 541 were
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diagnosed after the intended end of IPT (ITT analysis)
and 638 after the actual end of IPT (AT analysis, Fig. 2).
The median follow-up time, including the IPT period,
was 2.1 years and varied by cluster (ranging between 1.9
and 2.5 years).
In the ITT analysis, the overall TB incidence rate on
IPT was 1.3/100 pyrs (95 % CI, 1.0–1.6), whereas after
IPT it was 2.3 (95 % CI, 1.9–2.7) with a rate ratio (RR)
of 1.8 (95 % CI, 1.4–2.3). In the AT analysis, the rate on
IPT was 0.7/100 pyrs (95 % CI, 0.5–1.0), whereas after
IPT it was 2.3/100 pyrs (95 % CI, 1.9–2.7) with a RR of
3.1 (95 % CI, 2.3–4.3). Among those in the AT analysis
who took 6 months or more of IPT, the incidence rate
on IPT was 0.3/100 pyrs (95 % CI, 0.2–0.4) and off IPT
2.2/100 pyrs (95 % CI, 1.8–2.7), with a RR of 6.7 (95 %
CI, 5.6–8.0).
After the end of IPT, from the test for linearity, there
was some evidence for an increasing rate over time in
the ITT analysis and in the subgroup who took 6 months
or more of IPT, but not in the AT analysis (Fig. 3). The
results of the sensitivity analyses excluding possible TB
diagnoses were similar (Additional file 1: Figure S2). As
expected, the overall TB incidence rates were lower, but
the overall pattern of changes of TB incidence over time
was similar.
Risk factors associated with incident TB after IPT
A total of 17,446 (94 %) participants completed the
intended IPT period of 9 months alive, in the workforce
and not taking TB treatment, and formed the cohort for
the risk factor analysis for incident TB after IPT (Fig. 2).
They contributed 24,037 person-years, a median follow-
up of 1.4 years. Neither their baseline characteristics nor
the proportion of participants who took 6 months or
Table 1 Baseline characteristics of the study population
(n = 18,520)
Characteristic Total, n (col %) a
Sex Male 17,763 (95.9)
Age, years ≤29 2,456 (13.3)
30–39 4,919 (26.6)
40–49 7,782 (42.0)
≥50 3,362 (18.2)
Country of origin South Africa 10,501 (56.7)
Lesotho 5,178 (28.0)
Mozambique 1,854 (10.0)
Other 979 (5.3)
Years in workforce 0–9 4,874 (26.4)
10–19 5,017 (27.2)
20–29 5,846 (31.7)
≥30 2,724 (14.8)
Type of work Underground 16,821 (91.2)
Type of housing Hostel 10,913 (58.9)
Previous TB b 2,212 (12.0)
Previous IPT 79 (0.4)
Self-reported ART use 521 (2.8)
a Missing data (n): sex (1), age (46), country of origin (8), years in workforce
(59), type of work (77), type of residence (1), previous TB (14), previous IPT
(38), self-reported ART use (20)
b Timing of previous TB episodes: median 4.0 years (IQR, 1.8–8.9 years), 5 had
missing TB dates; 265 (12 %) episodes occurred in year prior to IPT
ART, Antiretroviral therapy; IPT, Isoniazid preventive therapy; IQR, Interquartile
range; N, Number; TB, Tuberculosis
18520 started IPT 
167 developed TB
87 died 
258 left workforce (illness)
562 left workforce (other reasons)
17446  completed 9months follow-up 
14700 completed follow -up (no TB)
541 developed TB
222 died
773 left workforce (illness)
1210 left workforce (other reasons)
18520 started IPT 
70 developed TB 
31 died
122 left workforce (illness)
328 left workforce (other reasons)
17969  stopped IPT alive and in workforce
14700 completed follow-up (no TB)
638 developed TB
278 died
908 left workforce (illness)
1445 left workforce (other reasons)
Intention to treat analysis: As-treated analysis:
A
fte
r 
IP
T
 
D
ur
in
g 
IP
T
Fig. 2 Participant flow and outcomes in the intention-to-treat and as-treated analyses. The duration on isoniazid preventive therapy was defined
as the intended duration (intention-to-treat analysis) and 30 days from the last dispensing date (as-treated analysis)
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more of IPT differed from the original cohort (Additional
file 1: Table S2). Characteristics of participants leaving the
workforce for reasons other than ill health were compared
to those of all participants. On average, these participants
were older, had been in the workforce longer and had had
TB previously (Additional file 1: Table S3).
After adjusting for sex, country of origin, self-reported
ART use and duration of IPT taken, there was strong
evidence of an increased hazard of TB following IPT
among participants who were older, doing underground
rather than surface work or had had TB before (Table 2).
A decreased hazard of TB was found in those not living
in a hostel or who had more IPT dispensed. Age and
years in the workforce were found to be co-linear; we
retained age in the model as this had been previously
shown to be the stronger risk factor for TB [23]. Ex-
cluding previous TB or self-reported ART use from
the model did not change the results, nor did adjust-
ment for calendar time.
The risk factor analysis in the AT cohort comprised
16,962 pyrs in the first year after IPT and 10,822 pyrs
from the second year onwards. The risk factor estimates
were very similar to the ITT analysis (Additional file 1:
Table S3).
Effect modification of risk factors by follow-up period
No evidence for effect modification of risk factors by
follow-up period was found; associated risk factors were
similar in the first year of follow-up compared to after-
wards (Table 3). This included the effect of number of
doses of IPT by follow-up time period. The results of this
analysis in the AT cohort were very similar (Additional
file 1: Table S4).
Comparison between the observed and estimated TB
incidence rate after IPT
The observed TB incidence rate during the first year
after IPT (ITT analysis) was 2.18/100 pyrs (95 % CI,
1.79–2.66). The crude average incidence rate of TB dis-
ease due to reinfection that might have occurred in the
first year after IPT was estimated at 1.28 per 100 pyrs.
At a cluster level, the estimated rates were consistently
lower than the rates observed in the data (Additional
file 1: Table S6).
Fig. 3 Rates of TB incidence over time during and after IPT in the Thibela TB study. (a) intention-to-treat analysis (intended duration of IPT),
(b) as-treated analysis (actual duration of IPT) and (c) as-treated analysis among the subset of optimal adherers (>6 months of IPT)). Rates were
adjusted for clustering by cluster. P values for overall association between TB incidence and time period of follow-up: (a) <0.001, (b) <0.001 and
(c) <0.001. P values for tests for linearity in TB incidence rates over time since IPT cessation: (a) 0.043, (b) 0.633 and (c) 0.077. P values for tests for
departure from linearity in TB incidence rates over time since IPT cessation: (a) 0.071, (b) 0.533 and (c) 0.003. CI, Confidence interval; IPT, Isoniazid
preventive therapy; pyrs, Person-years
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Discussion
This study, one of only few to specifically address the
durability of IPT, analysed the largest study cohort of
people on IPT in the ART era. The large number of
endpoints allowed for more power than previous
studies to examine the timing and risk factors of inci-
dent TB after IPT.
TB incidence increased soon after stopping IPT;
within 6 months, the TB incidence rate had more than
doubled and, within a year, it was within the range of
the community rate in the control clusters of the study
(2.95 per 100 pyrs; 95 % CI, 2.47–3.52) [6]. The previ-
ously published estimated TB incidence rate after IPT in
a subset of our study participants was in the same order
of magnitude [6]. The trend in incidence rates over time
was also comparable, although our much larger sample
size allowed us to look at this in more detail by assessing
follow-up time in shorter periods. Increasing rates after
IPT discontinuation have also been reported in high-
prevalence settings in the pre-ART [24, 25] and ART era
[4, 9]. In a medium-incidence setting (Brazil), TB inci-
dence rates among TST-positive HIV-positive persons
remained low for a median of 4.8 years following the
start of IPT [26, 27]. In addition to a lower force of in-
fection, a higher likelihood of cure due to a lower bacil-
lary burden in latent infection was proposed as an
explanation for the absence of rebound in their setting
compared to in high-prevalence settings.
Our study design does not allow conclusions about the
underlying mechanism of TB after IPT. Reinfection as a
mechanism for TB after IPT is very likely in this popula-
tion with a high annual risk of M. tuberculosis infection
Table 2 Risk factors for TB incidence after IPT (intention-to-treat)
Total n (%) pyrs TB HR (95 % CI) a P value aHR (95 % CI) a,f P value
Sex Male 16,704 (95.8) 23,036 523 1 0.08 1 0.73
Female 741 (4.2) 999 18 0.67 (0.42–1.08) 1.09 (0.67–1.80)
Age, years b ≤29 2,370 (13.6) 3,221 30 1 <0.001 1 <0.001
30–39 4,677 (26.8) 6,660 131 2.13 (1.43–3.17) 2.18 (1.46–3.25)
40–49 7,363 (42.2) 10,291 276 2.81 (1.92–4.10) 2.84 (1.92–4.18)
≥50 3,035 (17.4) 3,863 104 2.69 (1.79–4.06) 2.77 (1.81–4.23)
Country of origin South Africa 10,008 (57.4) 13,729 284 1 0.001 1 0.09
Lesotho 4,736 (27.2) 6,471 190 1.40 (1.17–1.68) 1.15 (0.95–1.40)
Mozambique 1,777 (10.2) 2,499 40 0.84 (0.60–1.18) 0.79 (0.57–1.11)
Other 917 (5.3) 1,327 27 1.06 (0.71–1.58) 0.82 (0.54–1.24)
Years in workforce c 0–9 4,683 (26.9) 6,391 85 1 <0.001
10–19 4,753 (27.3) 6,856 147 1.68 (1.28–2.20)
20–29 5,511 (31.7) 7,608 217 2.11 (1.64–2.71)
≥30 2,446 (14.1) 3,107 90 2.12 (1.57–2.86)
Type of work Surface 1,537 (8.8) 2,165 30 1 0.002 1 0.002
Underground 15,836 (91.2) 21,762 508 1.71 (1.18–2.48) 1.75 (1.20–2.54)
Type of housing Hostel 10,239 (58.7) 14,378 364 1 <0.001 1 0.004
Other 7,206 (41.3) 9,657 177 0.67 (0.55–0.80) 0.74 (0.61–0.91)
Previous TB No 15,427 (88.5) 21,413 430 1 <0.001 1 <0.001
Yes 2,005 (11.5) 2,605 111 2.08 (1.69–2.57) 1.89 (1.52–2.35)
Self-reported ART use No 16,956 (97.3) 23,386 523 1 0.42 1 0.64
Yes 471 (2.7) 625 17 1.23 (0.76–1.99) 0.89 (0.54–1.46)
Number of 1–2 4,640 (26.6) 6,513 159 1 0.001 1 <0.001
IPT prescriptions d,e 3–5 1,855 (10.6) 2,557 56 0.86 (0.64–1.17) 0.81 (0.59–1.09)
6+ 10,951 (62.8) 14,967 326 0.79 (0.65–0.97) 0.63 (0.51–0.77)
a Adjusted for cluster using a fixed effect
b P value for departure from linearity 0.002
c P value for departure from linearity 0.02
d P value for departure from linearity 0.83
e P value for linear trend 0.02
f On 17,332 participants, adjusted for all variables shown
aHR, Adjusted hazard ratio; ART, Antiretroviral therapy; CI, Confidence interval; HR, Hazard ratio; IPT, Isoniazid preventive therapy; pyrs, Person-years;
TB, Tuberculosis
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(estimated at 20 % [22]). TB contact studies in resource-
limited settings report the highest incidence of TB dis-
ease in the first year after acquisition [28], and therefore
reinfection could certainly be responsible for some of
the TB incidence in the first year after IPT. However, the
rapid increase in incidence after stopping seems suggest-
ive of a role for reactivation disease. Mathematical mod-
elling of the rebound in TB incidence in three sub-
Saharan African IPT trials in the pre-ART era estimated
reactivation of persistent latent infection to be respon-
sible for almost all TB after the end of IPT [29]. A re-
cently published mathematical model of the Thibela
study data also found that uncured latent infection
among HIV-positive miners may partly explain the lack
of population level impact [22].
Our crude estimate of the average incidence rate of
TB disease in the first year after IPT that might be at-
tributable due to reinfection [22] was lower than our ob-
served estimate of the TB incidence rate in the first year
after IPT. Despite the substantial variation in annual risk
of infection, this was consistent across clusters. This
supports our hypothesis that a proportion of the post-
IPT TB cases could be due to reactivation disease.
The rapid return of the TB incidence rate to baseline
levels followed by a stable rate over time could therefore
reflect a composite of both mechanisms: reactivation
disease gradually replaced by reinfection disease, eventu-
ally reaching a steady state of a mixture of the two
mechanisms. A similar time pattern in the mechanisms
underlying recurrent TB disease after TB treatment was
found in a molecular epidemiological study in South
Africa, where early recurrences were primarily relapses
and later recurrences were primarily reinfection [21].
Further, the episode start date was defined as the treat-
ment start date, which is likely substantially later than
the actual episode start date, and could have affected our
estimate of the possible contribution of reinfection.
Across southern Africa a high proportion of recurrent
TB disease is due to reinfection [18, 21, 30–32]. It has
been argued that latent infection confers some protec-
tion against reinfection in high-prevalence settings [33].
It is unclear whether this protection could be removed
by IPT, rendering the treated population at higher risk
of reinfection. In our IPT cohort the TB incidence rate
did not exceed that in the control arm, suggesting no in-
creased risk of TB after IPT in our cohort.
Table 3 Risk factors stratified by time after intended end of isoniazid preventive therapy (intention-to-treat)
Year 0–1 Year 1+
Total pyrs TB aHR (95 % CI) a pyrs TB aHR (95 % CI) a P value b
Sex Male 15,759 344 1 7,277 179 1 0.15
Female 709 15 0.82 (0.49–1.38) 290 3 0.35 (0.11–1.11)
Age, years ≤29 2,229 18 1 992 12 1 0.54
30–39 4,465 81 2.27 (1.36–3.79) 2,196 50 1.90 (1.01–3.56)
40–49 6,995 189 3.27 (2.01–5.30) 3,295 87 2.14 (1.17–3.91)
≥50 2,779 71 3.01 (1.79–5.06) 1,085 33 2.42 (1.25–4.70)
Years in workforce 0–9 4,436 58 1 1,956 27 1 0.15
10–19 4,543 84 1.48 (1.06–2.08) 2,314 63 2.05 (1.30–3.22)
20–29 5,213 155 2.23 (1.65–3.02) 2,395 62 1.86 (1.18–2.92)
≥30 2,229 61 2.03 (1.41–2.91) 878 29 2.35 (1.39–3.97)
Type of work Surface 1,465 20 1 700 10 1 0.98
Underground 14,932 339 1.71 (1.09–2.69) 6,830 169 1.72 (0.91–3.27)
Type of housing Hostel 9,681 236 1 4,697 128 1 0.57
Other 6,787 123 0.69 (0.55–0.86) 2,870 54 0.62 (0.45–0.85)
Previous TB No 14,618 281 1 6,795 149 1 0.63
Yes 1,838 78 2.15 (1.68–2.77) 767 33 1.93 (1.32–2.81)
Self-reported ART use No 16,013 346 1 7,373 177 1 0.82
Yes 439 12 1.28 (0.72–2.27) 186 5 1.13 (0.46–2.75)
Number of IPT prescriptions 1–2 4,321 99 1 2,192 60 1 0.86
3–5 1,715 36 0.88 (0.60–1.29) 842 20 0.84 (0.50–1.39)
6+ 10,433 224 0.82 (0.65–1.05) 4,534 102 0.79 (0.42–1.46)
a Adjusted for cluster. b Test for interaction for factor with time
aHR, Adjusted hazard ratio; ART, Antiretroviral therapy; CI, Confidence interval; HR, Hazard ratio; IPT, Isoniazid preventive therapy; pyrs, Person-years;
TB, Tuberculosis
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Our risk factor analysis showed that a longer duration
of IPT led to lower rates of TB after IPT. There was no
evidence for waning of this effect over time (≥12 months
compared to <12 months), although our analysis may
have had too short a follow-up period or may have been
underpowered to demonstrate this. An extended dur-
ation of IPT further reduced TB incidence among TST-
and HIV-positive persons in high incidence settings [7].
However, this effect also waned over time after the end
of IPT [9], suggesting that a longer duration of IPT does
not increase the durability of protection in high-
prevalence settings. Mathematical modelling corrobo-
rates this and further estimates that TB disease among
those treated with rifamycin-containing preventive ther-
apy is less likely to be due to reactivation, based on a
Ugandan study showing a slower rebound in participants
having used a regimen including rifamycins compared to
only isoniazid [25, 29]. Rifamycins have a higher steriliz-
ing potential; research into the use of regimens which
include them is ongoing. Thus far, trials comparing regi-
mens with isoniazid and rifamycin have not shown lower
rates of TB in a high transmission setting, although most
were not designed to show superiority [34, 35].
The risk factors for TB after IPT identified herein are
well-known and the same as before IPT [36], suggesting
IPT does not modify these. We found no evidence for
different risk factors in the first year compared to later
years after IPT. Follow-up might not have been long
enough or our analysis might have been underpowered
to identify a difference, however. The risk factors we
identified mediate risks of reinfection as well as reactiva-
tion, thereby not helping to differentiate between the
two underlying disease mechanisms.
The strengths of our analysis include the large number
of TB diagnoses and person-years of follow-up in a well-
characterised employment cohort resulting in higher
power than other studies to date to test hypotheses, in
particular relating to effect modification. Several import-
ant risk factors were not measured and could therefore
not be adjusted for, most importantly silicosis and HIV
status, which combine multiplicatively [36]. It would
have been interesting to stratify the trajectory of TB
rates after IPT by HIV status, as HIV-positive patients
(especially those with a low CD4 count) might progress
to disease faster after reinfection than HIV-negative pa-
tients. As the HIV prevalence among the gold miners is
higher than among the general population, this might
limit the direct comparability of our findings [37]. How-
ever, we applied the same HIV prevalence to arrive at
our modelled estimate of TB incidence after reinfection,
thereby not affecting our conclusions of the contribution
of the underlying mechanism of disease.
We were not able to include ART use as a time-
updated variable, whereas we know that ART use
increased during the course of the study [22] and is
highly associated with decreasing risk of TB disease
[22, 38]. Our analysis only included self-reported ART
usage, which likely represents misclassification; how-
ever, removing this variable from the multivariable
analysis did not change the estimates. Selection bias
may have arisen by a proportion of participants at
higher risk of TB leaving the workforce (during or
following IPT). Follow-up practices differed during
IPT and after IPT, possibly causing ascertainment bias
leading to an underestimate of TB incidence after
IPT. The analyses did not take account of possible in-
complete adherence to IPT, possibly leading to an
overestimate of IPT duration and therefore of TB in-
cidence rates during IPT. This potential misclassifica-
tion would only occur in the AT analysis, thereby not
impacting our main outcome and conclusions. Finally,
we did not have access to cluster-specific estimates of
HIV prevalence, case detection and pre-treatment loss
to follow-up. This might have led to an over- or
underestimate of the cluster-specific TB incidence
rates as calculated by our model.
Conclusions
The durability of protection by IPT was lost within 6–12
months in this population with a high annual risk of M.
tuberculosis infection and a high HIV prevalence. The
observed TB incidence in the first year after IPT was
higher than the crude estimate of the TB incidence at-
tributable to reinfection, suggesting that reactivation of
persistent latent infection played a role in the rapid re-
turn to baseline TB incidence. Further studies of the
durability of alternative (rifamycin-containing) TB pre-
ventive therapy regimens, alone or in combination with
ART, are warranted.
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